Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
May 11, 2023 08:00 ET
|
Avalyn Pharma Inc.
- Avalyn CEO to Present in Company Showcase and Moderate Panel Discussion at ATS RIS - - Results from Long-Term Treatment of Pulmonary Fibrosis with AP01 to be Presented at ATS - SEATTLE, May 11,...
Avalyn Pharma Presenting at BioEquity Europe
May 10, 2023 07:30 ET
|
Avalyn Pharma Inc.
Seattle, WA, May 10, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today...
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
April 11, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, April 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today reported...
Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
March 30, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
March 23, 2023 13:23 ET
|
Avalyn Pharma Inc.
SEATTLE , March 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
November 28, 2022 12:00 ET
|
Avalyn Pharma Inc.
SEATTLE , Nov. 28, 2022 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...